Literature DB >> 9224334

Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate.

N E Fleshner1, M O'Sullivan, W R Fair.   

Abstract

PURPOSE: We determined the prevalence of and risk factors for carcinoma in patients with 1 previously negative prostate biopsy.
MATERIALS AND METHODS: Transrectal ultrasound guided prostate needle biopsies were repeated in 130 men. Risk factors analyzed included age, pathological result of initial biopsy, inter-biopsy interval, prostate specific antigen (PSA), PSA density, PSA velocity, digital rectal examination, abnormal transrectal ultrasound and family history of prostate cancer.
RESULTS: A total of 39 patients (30%) had positive biopsies for cancer. Univariate analysis revealed that PSA more than 20 ng./ml. and abnormal transrectal ultrasound were more frequent in men with positive second biopsies. Using multivariate logistic regression analysis only PSA more than 20 ng./ml. was a significant risk factor (adjusted odds ratio 4.48, 95% confidence interval 1.02 to 20.1). We determined the incidence of carcinoma in patients who represent the lowest risk group as defined by PSA less than 10 ng./ml., PSA density less than 0.15 mg./ml./cm.3, PSA velocity less than 0.75, ng./ml. per year, no prostatic intraepithelial neoplasia plus negative transrectal ultrasound, digital rectal examination and family history. Of 21 patients who fit this cohort 5 (23.8%) had carcinoma on repeat biopsy.
CONCLUSIONS: A significant false-negative rate for initial transrectal ultrasound guided prostate biopsies exists. Baseline risk in lowest risk patients is sufficiently high such that one cannot define a subset of patients for whom repeat biopsy is unnecessary. We recommend repeat biopsy in all patients who meet the criteria for a transrectal ultrasound guided biopsy and in whom the initial biopsy is negative.

Entities:  

Mesh:

Year:  1997        PMID: 9224334

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

1.  Prostate cancer: A closer look at the initial results from the REDUCE trial.

Authors:  Peter H Gann
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

2.  Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.

Authors:  Peter H Gann; Angela Fought; Ryan Deaton; William J Catalona; Edward Vonesh
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

3.  Optimizing prostate biopsy strategies for the diagnosis of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

4.  A 49-year-old Hispanic male with intraepithelial neoplasia and focal atypia.

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

5.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

6.  Diagnostic yield of touch imprint cytology of prostate core needle biopsies.

Authors:  Sebastian Mannweiler; Karl Pummer; Marco Auprich; Günter Galle; Gábor Méhes; Manfred Ratschek; Oleksiy Tsybrovskyy; Farid Moinfar
Journal:  Pathol Oncol Res       Date:  2008-10-29       Impact factor: 3.201

Review 7.  MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results.

Authors:  Christiaan G Overduin; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

8.  Interstitial photoacoustic spectral analysis: instrumentation and validation.

Authors:  Haonan Zhang; Wan-Yu Chao; Qian Cheng; Shengsong Huang; Xueding Wang; Denglong Wu; Guan Xu
Journal:  Biomed Opt Express       Date:  2017-02-21       Impact factor: 3.732

9.  Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.

Authors:  Guan Xu; Mandy C Davis; Javed Siddiqui; Scott A Tomlins; Shengsong Huang; Lakshmi P Kunju; John T Wei; Xueding Wang
Journal:  Biomed Opt Express       Date:  2015-11-09       Impact factor: 3.732

10.  HPC2 variants and screen-detected prostate cancer.

Authors:  D Vesprini; R K Nam; J Trachtenberg; M A Jewett; S V Tavtigian; M Emami; M Ho; A Toi; S A Narod
Journal:  Am J Hum Genet       Date:  2001-03-14       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.